Table of Content

1. Introduction to Peptide Cancer Vaccine


2. Need of Peptide Vaccines
2.1 Why Peptides – More Desirable
2.2 Peptide Vaccines V/S Traditional Vaccines


3. Classification of Peptide Vaccines
3.1 On the Basis of Sources Obtained
3.2 On the Basis of Length
3.3 On the Basis of Epitopes


4. Mechanism of Action of Peptide Cancer Vaccines
4.1 Immunological Cells Activated by Peptide Cancer Vaccines
4.2 Procedure of Synthetic Peptide Vaccine Development


5. Clinical Trials Efficacy Study of Synthetic Peptide Analog Obtained From WT1 Oncoprotein against Acute Myeloid Leukemia
5.1 Basic Layout of the Study
5.2 Introduction to WT1 Peptide
5.3 Methodologies Involved In the Clinical Study
5.4 Results of the Clinical Trial Study


6. Wide Spectrum Action of Peptide Cancer Vaccines Against Major Cancer
6.1 Colorectal Cancer
6.2 Lung Cancer
6.3 Pancreatic Cancer
6.4 Gastric Cancer
6.5 Prostate Cancer
6.6 Breast Cancer


7. Global Peptide Cancer Vaccine Market Overview


8. Global Peptide Cancer Vaccine Market Trends
8.1 Optimized Cryptic Peptides
8.2 Therapeutic CpG Peptide-Based Cancer Vaccine
8.3 Personalized Neoantigen Vaccination with Synthetic Long Peptides
8.4 Recombinant Peptide Vaccine
8.5 p53 Peptide-Pulsed Dendritic Cells Cancer Vaccines


9. Global Peptide Cancer Vaccine Pipeline Overview
9.1 By Country
9.2 By Company
9.3 By Patient Segment
9.4 By Phase


10. Global Peptide Cancer Vaccine Clinical Trials Insight
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-III


11. LucaVax – First Commercially available Peptide Cancer Vaccine


12. Global Peptide Cancer Vaccine Market Dynamics
12.1 Market Driving Factors
12.2 Challenges Ahead For Peptide Cancer Vaccine Market Development


13. Peptide Cancer Vaccine: Promising Candidate of Cancer Immunotherapy
14. Competitive Landscape
14.1 Enzo Life Science (Alexis Biotech)
14.2 Antigen Express
14.3 BioLife Science
14.4 Immatics Biotechnologies
14.5 Immune Design
14.6 Imugene
14.7 Immunomedics
14.8 ISA Pharmaceuticals
14.9 Galena Biopharma
14.10 Generex Biotechnology Corporation
14.11 Lytix Biopharma
14.12 Merck (Merck Serono)
14.13 OncoTherapy Science
14.14 Oncothyreon
14.15 Pfizer
14.16 Phylogica
14.17 Symphogen (Receptor BioLogix)
14.18 Sumitomo Dainippon Pharma
14.19 TapImmune
14.20 Vaxon Biotech



List of Figures


Figure 1-1: Advantages of Peptide Cancer Vaccines

Figure 2-1: Peptides - Amino Acid & Proteins
Figure 2-2: Diversification of Vaccines
Figure 2-3: Sub-Unit Vaccines V/S Traditional Vaccines

Figure 3-1: Classification of Peptide Vaccine by Source
Figure 3-2: Classification on Basis of Length
Figure 3-3: On the Basis of Epitopes

Figure 4-1: Immunological Cells Activated By Peptide Cancer Vaccines
Figure 4-2: Procedure of Synthetic Peptide Cancer Vaccine Development
Figure 4-3: Determination of Antigen Components, Its Selection & Construction
Figure 4-4: Role of Adjuvants in Peptide Cancer Vaccines
Figure 4-5: Investigation of Efficiency & Immune Response to Synthetic Peptide Cancer Vaccine

Figure 5-1: Clinical Trial Study of WT1 Peptide Vaccine for Acute Myeloid Leukemia Patients
Figure 5-2: WT1 Peptide as a Marker for Cancer Therapy
Figure 5-3: Methodologies Involved In the Clinical Study

Figure 6-1: Peptides & Colorectal Cancer
Figure 6-2: Peptides & Lung Cancer
Figure 6-3: Peptides & Pancreatic Cancer
Figure 6-4: Peptides & Gastric Cancer
Figure 6-5: Peptides & Prostate Cancer
Figure 6-6: Peptides & Breast Cancer

Figure 7-1: Global – Peptide Therapeutic Market Size (US$ Billion), 2018 - 2026
Figure 7-2: Global – Total Peptide Therapeutic Market Size vs. Oncological Peptide Therapeutic Market Size (US$ Billion), 20120
Figure 7-3: Global – Oncological Peptide Therapeutics Market Share in Total Peptide market (%), 2020
Figure 7-4: Global – Peptide Oncology Drugs Market Size (US$ Billion), 2018 - 2026
Figure 7-5: Peptide Oncology Market – Regional Market Share (%), 2019

Figure 8-1: Optimized Cryptic Peptides
Figure 8-2: Therapeutic CpG Peptide-Based Cancer Vaccine
Figure 8-3: Personalized Neoantigen Vaccination with Synthetic Long Peptides
Figure 8-4: Recombinant Peptide Vaccine
Figure 8-5: p53 Peptide-Pulsed Dendritic Cells Cancer Vaccine

Figure 9-1: Global - Peptide Cancer Vaccine in Clinical Pipeline by Country, 2021 till 2026
Figure 9-2: Global - Peptide Cancer Vaccine in Clinical Pipeline by Company, 2021 till 2026
Figure 9-3: Global - Peptide Cancer Vaccine in Clinical Pipeline by Patient Segment, 2021 till 2026
Figure 9-4: Global - Peptide Cancer Vaccine in Clinical Pipeline by Phase, 2021 till 2026

Figure 12-1: Market Drivers of Peptide Cancer Vaccines
Figure 12-2: Peptide Cancer Vaccine: An Active Immunotherapy
Figure 12-3: Peptide Cancer Vaccine: A Personalized, Targeted Therapy
Figure 12-4: Peptide Cancer Vaccine: Highly Efficient, High Immunogenic Response Generating
Figure 12-5: Peptide Cancer Vaccine: Multiple Tumors Targeting Ability
Figure 12-6: Peptide Cancer Vaccine: A Viable Solution to Immunotolerance
Figure 12-7: Peptide Cancer Vaccine: Improves the Quality Of Life & is Cost Effective
Figure 12-8: Challenges of Peptide Cancer Vaccine: The Parameters Related To the Clinical Trials
Figure 12-9: Single Antigen Based Peptide Vaccine: Highly Prone To Failure
Figure 12-10: Lack of Standardized Parameters for Assessing the Result of Clinical Trials
Figure 12-11: Variable Therapeutic Window for Different Patients
Figure 12-12: Cancer Immunoediting: The Three Es; Tumor Elimination, Equilibrium & Escape

Figure 14-1: Enzo Life Science Pipeline
Figure 14-2: Immatics Biotechnologies Pipeline
Figure 14-3: Immune Design Pipeline
Figure 14-4: Imugene Pipeline
Figure 14-5: ISA Pharmaceuticals Pipeline
Figure 14-6: Galena Biopharma Pipeline
Figure 14-7: Generex Biotechnology Pipeline
Figure 14-8: Lytix Biopharma Pipeline
Figure 14-9: Merck Clinical Pipeline
Figure 14-10: Onco Therapy Science Pipeline
Figure 14-11: Oncothyreon Pipeline
Figure 14-12: Sumitomo Dainippon Pharma Pipeline
Figure 14-13: Tapimmune Pipeline
Figure 14-14: Vaxon Biotech Pipeline